Portfolio News

Myomo to Present at Noble Capital Markets’ 14th Annual Investor Conference

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced that it will be presenting at NobleCon14 - Noble Capital Markets’ Fourteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida on Monday, January 29th at 11:00 AM EST - Studio 4. Chairman and Chief Executive Officer Paul R. Gudonis will be presenting, as well as meeting with investors. Read more >>
Read more...

3 Game-Changing Health Gadgets Spotted at CES

In advance of CES, I was alerted to two products in this category that I wanted to check out. The first is called eSight, which are electronic glasses that let the legally blind see. In the demo I saw, a legally blind woman using these glasses could see the street from the 30th floor of a hotel suite and make out what people were wearing at street level. Read more >>
Read more...

From Startup to Publicly Traded Company: Story of Corbus Pharmaceuticals

The following post is from Antonette Ho, Group Operations Manager at Boston Harbor Angels. Corbus Pharmaceuticals Wins Exit of the Year Award Corbus Pharmaceuticals is a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases with clear unmet needs. One of the great successes in the Boston Harbor Angels portfolio, Corbus was awarded Exit of the Year at the annual end-of-year general meeting in December 2017. Yuval Cohen, CEO of Corbus Pharmaceuticals and Mark Tepper, President &...
Read more...

Go Write the Ad: Tips from David Friend, CEO and Co-founder of Wasabi

The following post is from Antonette Ho, Group Operations Manager at Boston Harbor Angels. Wasabi Wins IT Startup of the Year This past December, the Boston Harbor Angels hosted its annual end-of-year general meeting. During the meeting, Wasabi was honored as IT Startup of the Year. Wasabi is a new cloud storage company. After the awards, Mic Williams, President and Founder of Boston Harbor Angels, interviewed David Friend, CEO and co-founder of Wasabi. During the interview, Friend shared some history about his...
Read more...

Siamab Therapeutics to Present New Data on its ST1 Antibody Therapeutic Program Targeting Tumor-Associated STn and MDSCs at Biotech Showcase™ 2018

Siamab Therapeutics, Inc., a biopharmaceutical company developing novel cancer therapeutics, today announced that Jeff Behrens, president and chief executive officer, will present at the 10th annual Biotech Showcase™ conference in San Francisco on Tuesday, January 9, 2018 at 1:45 p.m. PT. The conference will be held January 8-10, 2018, at the Hilton San Francisco Union Square. Read more >>
Read more...